合肥立方制药股份有限公司第六届董事会第四次会议决议公告

Core Viewpoint - The company has approved the use of up to RMB 300 million of idle funds for cash management to enhance fund utilization efficiency and generate returns while ensuring normal operations are not affected [3][10][21]. Group 1: Board Meeting Details - The sixth board meeting of Hefei Lifan Pharmaceutical Co., Ltd. was held on February 5, 2026, with all 8 directors present, including some participating via communication methods [2][5]. - The meeting was chaired by the company's chairman, Ji Junqiu, and complied with relevant legal and regulatory requirements [2][3]. Group 2: Cash Management Proposal - The board approved a proposal to use idle funds for cash management, specifically for purchasing low-risk investment products with high safety and liquidity [3][10][21]. - The investment amount is capped at RMB 300 million, with a validity period of 12 months from the approval date, allowing for fund rollover within this timeframe [10][11]. Group 3: Investment Strategy and Implementation - The company plans to invest in low-risk products that do not involve pledging, ensuring the safety of the principal [10][11]. - The management team is authorized to make investment decisions and sign relevant contracts, with the finance department responsible for organizing the investment activities [12][21]. Group 4: Impact on Company Operations - The cash management initiative is designed to improve fund efficiency without affecting the company's daily operational liquidity or core business development [18][20]. - The expected outcome is to enhance overall performance and benefit all shareholders [18][20]. Group 5: Approval Opinions - The audit committee and board of directors have both approved the cash management proposal, confirming it will not harm the interests of the company or its shareholders [19][20].